Treatment of Multiple Myeloma at Early Relapse

EP: 1.The Evolving Landscape of Newly Diagnosed Multiple Myeloma

EP: 2.Highlights from ASH 2023 in Transplant-Eligible NDMM

EP: 3.Advances in the Treatment of High-Risk MM

EP: 4.Role of Transplant and MRD in Newly Diagnosed MM

EP: 5.The Evolving Treatment Paradigm for Transplant Ineligible MM

Now Viewing

EP: 6.Treatment of Multiple Myeloma at Early Relapse

EP: 7.Potential Role for CAR T-Cell Therapy in MM at Early Relapse

EP: 8.Updates on BCMA-Targeting Bispecifics in MM

EP: 9.Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

EP: 10.Step-Up Dosing Practices for Bispecifics in Multiple Myeloma

EP: 11.Adverse Effects Related to Bispecifics in Multiple Myeloma

EP: 12.GPRC5D-Targeting Bispecifics in Multiple Myeloma

EP: 13.CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

EP: 14.Treatment Considerations and Sequencing in Multiple Myeloma

This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.

The discussion focuses on treatment selection in early relapse multiple myeloma after initial therapy. Key factors include patient comorbidities, pace of relapse, high-risk features, prior toxicity, and duration of benefit from prior lines. Refractoriness to lenalidomide maintenance is increasingly common and complicates choices.

For standard-risk relapsed patients, triplet regimens like carfilzomib-cyclophosphamide-dexamethasone (KCd) or carfilzomib-daratumumab-dexamethasone (DKd) are recommended based on efficacy data from the phase 3 CANDOR and IKEMA trials vs doublets. However, in frail, older patients, combinations like daratumumab-pomalidomide-dexamethasone (DPd) or isatuximab-pomalidomide-dexamethasone (IPd) may be better tolerated while still improving outcomes over pomalidomide-dexamethasone.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.